기면병 및 과다수면 진단과 치료의 최신 지견
Recent Updates on Narcolepsy and Hypersomnia
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Narcolepsy is a chronic neurological sleep disorder caused by hypocretin neuron loss, resulting in excessive daytime sleepiness, disturbed nocturnal sleep, and intrusions of aspects of rapid eye movement sleep in wakefulness, such as cataplexy, sleep paralysis, and hypnopompic/hypnagogic hallucinations. Narcolepsy disrupts the maintenance and orderly occurrence of the wake and sleep stages. Cataplexy is a highly specific symptom of narcolepsy, but many other symptoms can be observed in a variety of sleep disorders. The diagnosis of narcolepsy type 1 requires a history of excessive daytime sleepiness and one of the following : 1) a low cerebrospinal fluid hypocretin-1 level or 2) cataplexy and a positive multiple sleep latency test result. The diagnosis of narcolepsy type 2 requires a history of excessive daytime sleepiness and a positive mean sleep-latency test result. The mean sleep-latency test must be preceded by nighttime polysomnography to exclude other sleep disorders and to document adequate sleep. The mean sleep-latency test result can be falsely positive in other sleep disorders, such as shift work, sleep apnea, or sleep deprivation, and it is influenced by age, sex, and puberty. Modafinil and armodafinil can reduce the excessive daytime sleepiness without many of the side effects associated with older stimulants. Although there is no cure for narcolepsy, the treatments are often effective and include both behavioral and pharmacologic approaches.
Abstract
Narcolepsy is a chronic neurological sleep disorder caused by hypocretin neuron loss, resulting in excessive daytime sleepiness, disturbed nocturnal sleep, and intrusions of aspects of rapid eye movement sleep in wakefulness, such as cataplexy, sleep paralysis, and hypnopompic/hypnagogic hallucinations. Narcolepsy disrupts the maintenance and orderly occurrence of the wake and sleep stages. Cataplexy is a highly specific symptom of narcolepsy, but many other symptoms can be observed in a variety of sleep disorders. The diagnosis of narcolepsy type 1 requires a history of excessive daytime sleepiness and one of the following : 1) a low cerebrospinal fluid hypocretin-1 level or 2) cataplexy and a positive multiple sleep latency test result. The diagnosis of narcolepsy type 2 requires a history of excessive daytime sleepiness and a positive mean sleep-latency test result. The mean sleep-latency test must be preceded by nighttime polysomnography to exclude other sleep disorders and to document adequate sleep. The mean sleep-latency test result can be falsely positive in other sleep disorders, such as shift work, sleep apnea, or sleep deprivation, and it is influenced by age, sex, and puberty. Modafinil and armodafinil can reduce the excessive daytime sleepiness without many of the side effects associated with older stimulants. Although there is no cure for narcolepsy, the treatments are often effective and include both behavioral and pharmacologic approaches.
참고문헌 (28)
- Dauvilliers Y, "Narcolepsy with cataplexy", Lancet, 369, pp.499~511 (2007)
- Aldrich MS, "The clinical spectrum of narcolepsy and idiopathic hypersomnia", Neurology, 46, pp.393~401 (1996)
- American Academy of Sleep Medicine, "International classification of sleep disorders" (2014), American Academy of Sleep Medicine
- Dauvilliers Y, "Age at onset of narcolepsy in two large populations of patients in France and Quebec", Neurology, 57, pp.2029~2033 (2001)
- Zeman A, "Narcolepsy and excessive daytime sleepiness", BMJ, 329, pp.724~728 (2004)
- Mattarozzi K, "Clinical, behavioural and polysomnographic correlates of cataplexy in patients with narcolepsy", cataplexy, 2008, pp.9, 425~433
- Overeem S, "The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1deficiency", Sleep Med, 12, pp.12~18 (2011)
- Ohayon MM, "Hypnagogic and hypnopompic hallucinations: pathological phenomenon?", Br J Psychiatry, 169, pp.459~467 (1996)
- Guilleminault C, "Insomnia, narcolepsy, and sleep apneas", Bull Physiopathol Respir (Nancy), 8, pp.1127~1138 (1972)
- Morrish E, "Factors associated with a delay in the diagnosis of narcolepsy", Sleep Med, 5, pp.37~41 (2004)
- Mignot E, "HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients", Sleep, 20, pp.1012~1020 (1997)
- Pelin Z, "HLADQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group", Tissue Antigens, 51, pp.96~100 (1998)
- Haba-Rubio J, "Narcolepsy with cataplexy associated with H1N1 vaccination", Rev Neurol (Paris), 167, pp.563~566 (2011)
- Han F, "Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China", Ann Neurol, 70, pp.410~417 (2011)
- Poli F, "Narcolepsy as an adverse event following immunization:case definition and guidelines for data collection, analysis and presentation", Vaccine, 31, pp.994~1007 (2013)
- Ohayon MM, "How age influences the expression of narcolepsy", J Psychosom Res, 59, pp.399~405 (2005)
- Mignot E, "The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias", Arch Neurol, 59, pp.1553~1562 (2002)
- de Lecea L, "The hypocretins : hypothalamus-specific peptides with neuroexcitatory activity", Proc Natl Acad Sci U S A, 95, pp.322~327 (1998)
- Lin L, "The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin(orexin)receptor 2 gene", Cell, 98, pp.365~376 (1999)
- Nishino S, "Hypocretin(orexin)deficiency in human narcolepsy", Lancet, 355, pp.39~40 (2000)
- Baumann CR, "Challenges in diagnosing narcolepsy without cataplexy : a consensus statement", Sleep, 37, pp.1035~1042 (2014)
- Moscovitch A, "The positive diagnosis of narcolepsy and narcolepsy’s borderland", Neurology, 43, pp.55~60 (1993)
- van den Hoed J, "Disorders of excessive daytime somnolence : polygraphic and clinical data for 100 patients", Sleep, 4, pp.23~37 (1981)
- Boutrel B, "What keeps us awake : the neuropharmacology of stimulants and wakefulness-promoting medications", Sleep, 27, pp.1181~1194 (2004)
- Mignot E, "Modafinil binds to the dopamine uptake carrier site with low affinity", Sleep, 17, pp.436~437 (1994)
- Lankford DA, "Armodafinil : a new treatment for excessive sleepiness", Expert Opin Investig Drugs, 17, pp.565~573 (2008)
- Wozniak DR, "Unmet needs of patients with narcolepsy : perspectives on emerging treatment options", Nat Sci Sleep, 7, pp.51~61 (2015)
- Kent JM, "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression", Lancet, 355, pp.911~918 (2000)